Oncternal Therapeutics EBITDA vs. Current Valuation
| ONCT Stock | USD 0.75 0.04 5.63% |
EBITDA | First Reported 2010-12-31 | Previous Quarter 2.2 M | Current Value 2.3 M | Quarterly Volatility 16.8 M |
For Oncternal Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Oncternal Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Oncternal Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Oncternal Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Oncternal Therapeutics over time as well as its relative position and ranking within its peers.
Oncternal |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncternal Therapeutics. If investors know Oncternal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncternal Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.69) | Revenue Per Share 0.73 | Quarterly Revenue Growth 1.76 | Return On Assets (0.76) | Return On Equity (1.50) |
The market value of Oncternal Therapeutics is measured differently than its book value, which is the value of Oncternal that is recorded on the company's balance sheet. Investors also form their own opinion of Oncternal Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Oncternal Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncternal Therapeutics' market value can be influenced by many factors that don't directly affect Oncternal Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oncternal Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncternal Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncternal Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Oncternal Therapeutics Current Valuation vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Oncternal Therapeutics's current stock value. Our valuation model uses many indicators to compare Oncternal Therapeutics value to that of its competitors to determine the firm's financial worth. Oncternal Therapeutics is considered to be number one stock in ebitda category among its peers. It is rated below average in current valuation category among its peers . At this time, Oncternal Therapeutics' EBITDA is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Oncternal Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Oncternal Current Valuation vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Oncternal Therapeutics |
| = | 2.23 M |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Oncternal Therapeutics |
| = | (12.17 M) |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Oncternal Current Valuation vs Competition
Oncternal Therapeutics is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is now estimated at about 1.03 Billion. Oncternal Therapeutics has negative current valuation of (12.17 Million) having no influence on the industry.
Oncternal Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Oncternal Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Oncternal Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Oncternal Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Oncternal Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 3 K | 3.1 K | |
| Operating Income | -41.7 M | -43.8 M | |
| Net Loss | -39.5 M | -41.5 M | |
| Income Tax Expense | -41.7 M | -39.6 M | |
| Income Before Tax | -39.5 M | -41.5 M | |
| Total Other Income Expense Net | 2.2 M | 2.3 M | |
| Net Loss | -41.7 M | -43.8 M | |
| Non Operating Income Net Other | 903.9 K | 503.1 K | |
| Net Loss | -50.8 M | -53.3 M | |
| Net Interest Income | 2.3 M | 2.4 M | |
| Interest Income | 2.3 M | 2.4 M | |
| Change To Netincome | 8.5 M | 9 M | |
| Net Loss | (13.43) | (14.10) | |
| Income Quality | 0.81 | 0.56 | |
| Net Income Per E B T | 1.13 | 1.24 |
Oncternal Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Oncternal Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Oncternal Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Oncternal Therapeutics' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Oncternal Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Balance Of Power Now
Balance Of PowerCheck stock momentum by analyzing Balance Of Power indicator and other technical ratios |
| All Next | Launch Module |
Use Investing Themes to Complement your Oncternal Therapeutics position
In addition to having Oncternal Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Gambling Thematic Idea Now
Gambling
Companies that are related to providing gambling services across multiple geographical areas by investing, exploring, or producing software, hardware, and related infrastructure for running gambling operations or trading speculative assets. The Gambling theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Gambling Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Oncternal Stock Analysis
When running Oncternal Therapeutics' price analysis, check to measure Oncternal Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncternal Therapeutics is operating at the current time. Most of Oncternal Therapeutics' value examination focuses on studying past and present price action to predict the probability of Oncternal Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncternal Therapeutics' price. Additionally, you may evaluate how the addition of Oncternal Therapeutics to your portfolios can decrease your overall portfolio volatility.